BCPC vs IMPP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: IMPP is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BCPC and IMPP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BCPC and IMPP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Balchem Corporation is a specialty ingredients company organized into three segments: Human Nutrition and Health (choline nutrients, encapsulated ingredients, flavor and food systems), Animal Nutrition and Health (microencapsulated feed additives, chelated minerals, and choline chloride for livestock and pets), and Specialty Products (ethylene-oxide sterilization for medical devices, plus fumigants for food safety). It is a leader in choline chemistry and microencapsulation, selling into food, beverage, dietary supplement, animal feed, and healthcare end markets that tend to hold up through economic cycles.

Full BCPC guide

Imperial Petroleum Inc. is a ship-owning company headquartered in Athens, Greece, that provides seaborne transportation of petroleum products, crude oil, and dry cargo. It was spun off from StealthGas in December 2021 and trades on the Nasdaq Capital Market, with its common stock under IMPP and an 8.75% Series A Cumulative Redeemable Perpetual Preferred under IMPPP. Its fleet mixes MR product tankers, a suezmax, and handysize, supramax and kamsarmax drybulk carriers, and management has been growing the fleet toward roughly 26 vessels on the water in 2026 with additional deliveries agreed. Because much of the fleet operates in the spot market, revenue and profit track daily charter rates closely, which makes results swing sharply quarter to quarter with the strength of tanker and drybulk markets.

Full IMPP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BCPC drivers: Human Nutrition and Health momentum; Specialty Products and medical sterilization.
• IMPP drivers: Debt-free balance sheet and asset backing; Fleet growth into a strong shipping cycle.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Balchem trades at a premium earnings multiple, so any slowdown in growth or margin pressure could compress the valuation meaningfully. For IMPP, the dominant risk is charter-rate cyclicality: with heavy spot exposure, Imperial's profits can fall as fast as they rose if tanker or drybulk rates weaken, so recent record quarters should not be extrapolated.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BCPC if you believe its drivers more; IMPP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BCPC and IMPP guides.

BCPC. Balchem posted record first-quarter 2026 net sales of about $271 million, up roughly 8% year over year, with adjusted EBITDA near $74 million and another quarter of year-over-year adjusted EBITDA growth. Trailing revenue is around $1.06 billion with net income near $158 million. The roughly 34x earnings multiple reflects the market pricing in the company's long consistency rather than any near-term acceleration.

IMPP. All figures are approximate, tied to the asOf date, and should be verified against the latest company filings before acting. As a foreign private issuer, Imperial reports on Form 6-K and 20-F, so the cadence and format differ from US domestic filers. For a spot-exposed shipping company, trailing earnings reflect where charter rates recently sat in the cycle and may not repeat, so the durability of cash flows and the pace of capital returns matter more than any point-in-time P/E. The recurring question for this stock is whether management narrows the gap to asset value through buybacks and returns, or issues more equity and widens it again.

Headline figures (approximate, July 2026): BCPC shows revenue (ttm) ~$1.06B, net income (ttm) ~$158M, q1 2026 net sales ~$271M (+8% YoY), q1 2026 adjusted eps ~$1.33; IMPP shows revenue trend Grew year over year in 2025 (reported around the low $160 millions), with 2026 quarters described by the company as among its best ever; figures are approximate, verify live, profitability Solidly profitable through the strong 2024-2026 tanker cycle, with meaningful net income and EBITDA; earnings are highly sensitive to charter rates and can swing sharply, balance sheet Debt-free with a large cash and time-deposit position (reported around the high $100 millions at year-end 2025); unusually strong for a company this size, verify current figures, market cap tier Micro-cap; the equity value has at times sat below reported cash plus fleet value, the basis of the deep-value thesis.

BCPC and IMPP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BCPC and IMPP exposure against your real portfolio. It is not an investment adviser.